The antiviral drug Molnupiravir prevents the coronavirus from progressing to severe disease.
Scientists from the Institute for Biomedical Sciences, Georgia State University, have found a means to block the transmission of coronavirus.
A team of experts led by Professor Richard Plemper, have analyzed the effect of the antiviral drug MK-4482 / EIDD-2801 or Molnupiravir on SARS-CoV-2, which is effective against influenza viruses and has a broad spectrum of action against RNA-containing viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission. MK-4482/EIDD-2801 could be game-changing.”
says Dr. Plemper.
As a result of laboratory studies on animals, it turned out that the agent showed good results at an early stage of the disease. So, it does not allow COVID-19 to progress to a severe form, shortens the duration of the infection in the body and can block the transmission of the virus during withing 24 hours.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission. These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19”
As explained by the Professor.
According to the study, patients with COVID-19 will stop transmitting SARS-CoV-2 to others within 24 hours after starting treatment.
The results of the study are published in the journal Nature Microbiology.